

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5869532

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PATRICK F. KELLY	12/04/2019
JEFF DAVIS	06/06/2019
DUNCAN WALKER	05/25/2019
SUSAN ASHWELL	08/29/2019
BLYTHE THOMSON	12/12/2019
RECEIVING PARTY DATA	
Name:	FORMA THERAPEUTICS, INC.
Street Address:	500 ARSENAL STREET
Internal Address:	SUITE 100
City:	WATERTOWN
State/Country:	MASSACHUSETTS
Postal Code:	02472
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	16414505
PCT Number:	US1932747
CORRESPONDENCE DATA	
Fax Number:	(617)502-5002
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	617-248-5000
Email:	PatentDocket@choate.com
Correspondent Name:	CHOATE HALL & STEWART LLP-PATENT DOCKET
Address Line 1:	TWO INTERNATIONAL PLACE
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	2012552-0944 & -0943
NAME OF SUBMITTER:	ERICA M. D'AMATO
SIGNATURE:	/Erica M. D'Amato/
DATE SIGNED:	12/16/2019

Total Attachments: 9

source=2012552-0944_Assignment#page1.tif

source=2012552-0944_Assignment#page2.tif

source=2012552-0944_Assignment#page3.tif

source=2012552-0944_Assignment#page4.tif

source=2012552-0944_Assignment#page5.tif

source=2012552-0944_Assignment#page6.tif

source=2012552-0944_Assignment#page7.tif

source=2012552-0944_Assignment#page8.tif

source=2012552-0944_Assignment#page9.tif

JOINT ASSIGNMENT

WHEREAS, each of the below-named inventors whose name and residence is set forth in the following Table 1:

Inventor Name	City, State
1. Patrick F. Kelly	Concord, Massachusetts
2. Alan Collis	Lexington, Massachusetts
3. Jeff Davis	Hingham, Massachusetts
4. Duncan Walker	Boulder, Colorado
5. Susan Ashwell	Carlisle, Massachusetts
6. Blythe Thomson	Newton, Massachusetts

Table 1

hereby declares and agrees, on behalf of himself/herself and all of his/her successors and assigns that each is aware of the patent application(s) entitled:

INHIBITING MUTANT IDH-1; and

☐ prepared for filing in the United States Patent and Trademark Office; or

☒ identified by United States Application No. 16/414,505
filed in the United States Patent and Trademark Office on May 16, 2019; and

☒ identified by International Patent Application No. PCT/US2019/032747
filed on May 16, 2019; and

☒ and is also aware of the following priority applications:

Application No.	Filed
62/812367	March 1, 2019
62/798690	January 30, 2019
62/798687	January 30, 2019
62/798684	January 30, 2019
62/798681	January 30, 2019
62/798677	January 30, 2019
62/773562	November 30, 2018
62/692605	June 29, 2018
62/692604	June 29, 2018
62/692601	June 29, 2018
62/692598	June 29, 2018
62/680571	June 4, 2018
62/680566	June 4, 2018

62/680562	June 4, 2018
62/680560	June 4, 2018
62/672462	May 16, 2018
62/672461	May 16, 2018

WHEREAS, **FORMA Therapeutics, Inc.** (hereinafter "ASSIGNEE"), having a usual place of business at **500 Arsenal Street, Suite 100, Watertown, Massachusetts 02472**, desires to acquire or confirm an interest therein;

NOW, THEREFORE, to all whom it may concern be it known that, in consideration of agreements previously and duly entered into between the parties, and/or for other good and valuable consideration, the receipt of which is hereby acknowledged, each of us has sold, assigned, and transferred and/or do hereby sell, assign, and transfer unto said ASSIGNEE, its successors, assigns, and legal representatives, my entire right, title, and interest in and throughout the United States of America, its territories and all foreign countries, in and to any and all inventions described in the patent application, and/or any priority applications noted above, including any right of priority thereto; and hereby confirm that my sale, assignment and transfer is and was effective at least as of the filing date of the patent application and/or priority application. Our sale, assignment and transfer applies to the above-referenced patent application, and to any application that is based in whole or in part on the patent application, including any divisional, continuing, substitute, renewal, reissue, reexamination and other applications, for example that claim priority to the patent application. Also, this sale, assignment and transfer pertains to any and all other rights arising under or pursuant to any and all international agreements, treaties, or laws relating to the protection of industrial property, including all rights of priority under the International Convention for the Protection of Industrial Property, and in and to any such patent(s) as may issue thereon including any and all original and reissued patents which have been or shall be issued in the United States and foreign countries; said inventions, applications, and patent(s) to be held and enjoyed by ASSIGNEE for its own use and for its successors, assigns and legal representatives, to the full end of the term for which said patent(s) may be granted as fully and entirely as the same would have been held by each of us had this sale, assignment and transfer not been made;

AND, each of us hereby acknowledges that this Assignment, being of our entire right, title, and interest in and to the inventions, carries with it the right in ASSIGNEE, by attorneys and agents of ASSIGNEE selection, to apply for and receive any and all patent(s) for said inventions in its own name;

AND, each of us hereby further agrees for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the patent(s) to ASSIGNEE, its successors, assignees, and legal representatives, but at its expense and charges, including the execution of application for patents in foreign countries, the execution of substitution, reissue, divisional or continuation applications, and the giving of testimony, preliminary statements, or other statements in any interference or other proceeding in which the inventions or any applications or patents directed to the inventions may be involved by communicating to the ASSIGNEE all facts we know relating to the inventions and their history, and generally by doing everything possible

which ASSIGNEE shall consider desirable for aiding in securing and maintaining proper patent protection for the inventions and for vesting title in the inventions and all applications for patent and all patents on the inventions in ASSIGNEE;

AND, each of us further hereby authorizes ASSIGNEE or its attorneys or agents to insert the correct application number(s) and/or filing date(s) into this assignment document, if appropriate;


AND, each of us hereby appoints ASSIGNEE as our common agent for purposes of prosecuting international patent applications and any national patent applications for which such common agency is recognized;

AND, each of us hereby requests the Commissioner for Patents of the United States Patent and Trademark Office to issue any and all patent(s) as shall be granted upon said application or applications based thereon to ASSIGNEE, its successors, assigns, and legal representatives;

AND, each of us covenants with said ASSIGNEE that no assignment, grant, mortgage, license, or other agreement affecting the rights and property herein conveyed has been made to others by us, and that full right to convey the same as herein expressed is possessed by us.

Signature: 
Patrick F. Kelly

Date: 4-Dec-2019

Witness Signature: 

Witness Name (printed): Lea Florentino

Witness Signature: 

Witness Name (printed): Joy Chavis

Signature: _____
Alan Collis


Date: _____

Witness Signature: _____


Witness Name (printed): _____

Witness Signature: _____

Witness Name (printed): _____

Signature: 
Jeff Davis

Date: 06-Jun-2019

Witness Signature: 

Witness Name (printed): Wei Lu

Witness Signature: 

Witness Name (printed): Andrew Olaharski

Signature: 
Duncan Walker

Date: 5/25/19.

Witness Signature: 

Witness Name (printed): Bridgette Chandhoke

Witness Signature: 

Witness Name (printed): Leah Robins Schnairson

Signature: S Ashwell
Susan Ashwell

Date: 29 Aug 2019

Witness Signature: [Signature]


Witness Name (printed): Jennifer Dawson


Witness Signature: [Signature]

Witness Name (printed): CAMIL SAYEGH


Signature: 
Blythe Thomson

Date: 12-DEC-2019

Witness Signature: 
Witness Name (printed): Ashley Costello

Witness Signature: 
Witness Name (printed): Jay Chavira

The undersigned (whose title is supplied below) is authorized to act on behalf of
FORMA Therapeutics, Inc.

Signature:  Date: 12/12/19
Name (printed): Jeannette Potts
Title (printed): SVP, General Counsel and Corporate Secretary